CL2012003054A1 - Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión. - Google Patents

Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión.

Info

Publication number
CL2012003054A1
CL2012003054A1 CL2012003054A CL2012003054A CL2012003054A1 CL 2012003054 A1 CL2012003054 A1 CL 2012003054A1 CL 2012003054 A CL2012003054 A CL 2012003054A CL 2012003054 A CL2012003054 A CL 2012003054A CL 2012003054 A1 CL2012003054 A1 CL 2012003054A1
Authority
CL
Chile
Prior art keywords
antibody
ang
prevention
nucleic acid
pharmaceutical composition
Prior art date
Application number
CL2012003054A
Other languages
English (en)
Inventor
Anita Kavlie
Christian Klein
Joerg Thomas Regula
Werner Scheuer
Ulrich Brinkmann
Remko Albert Griep
Klaus Kaluza
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40585738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003054(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2012003054A1 publication Critical patent/CL2012003054A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticuerpos contra la angiopoyetina 2 humana (ANG-2); composición farmacéutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevención de metástasis; ácido nucleico que codifica dicho anticuerpo; vector de expresión.
CL2012003054A 2008-12-16 2012-10-30 Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión. CL2012003054A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08021835 2008-12-16

Publications (1)

Publication Number Publication Date
CL2012003054A1 true CL2012003054A1 (es) 2012-12-14

Family

ID=40585738

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2011001285A CL2011001285A1 (es) 2008-12-16 2011-05-31 Anticuerpo que se une a la angiopoyetina-2 humana (ang-2 o ang2 o angpt2); acido nucleico que lo codifica; vector de expresion recombinante; celula huesped; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2012003054A CL2012003054A1 (es) 2008-12-16 2012-10-30 Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2011001285A CL2011001285A1 (es) 2008-12-16 2011-05-31 Anticuerpo que se une a la angiopoyetina-2 humana (ang-2 o ang2 o angpt2); acido nucleico que lo codifica; vector de expresion recombinante; celula huesped; composicion farmaceutica que lo comprende; y su uso para tratar cancer.

Country Status (34)

Country Link
US (12) US8133979B2 (es)
EP (1) EP2379592B1 (es)
JP (2) JP5559191B2 (es)
KR (2) KR101445518B1 (es)
CN (3) CN102257008A (es)
AR (2) AR074756A1 (es)
AU (1) AU2009328613B2 (es)
BR (2) BRPI0923434A2 (es)
CA (2) CA2916481C (es)
CL (2) CL2011001285A1 (es)
CR (2) CR20110321A (es)
CY (1) CY1116264T1 (es)
DK (1) DK2379592T3 (es)
EC (2) ECSP11011139A (es)
ES (1) ES2534635T3 (es)
HK (2) HK1172349A1 (es)
HR (1) HRP20150439T1 (es)
HU (1) HUE024545T2 (es)
IL (2) IL213039A (es)
MA (1) MA32876B1 (es)
MX (1) MX2011005908A (es)
MY (2) MY155654A (es)
NZ (2) NZ592856A (es)
PE (2) PE20140814A1 (es)
PH (1) PH12013502192A1 (es)
PL (1) PL2379592T3 (es)
PT (1) PT2379592E (es)
RU (2) RU2569107C2 (es)
SG (1) SG172216A1 (es)
SI (1) SI2379592T1 (es)
TW (2) TWI482631B (es)
UA (2) UA105151C2 (es)
WO (1) WO2010069532A1 (es)
ZA (2) ZA201103990B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
NZ586701A (en) 2008-01-03 2013-07-26 Scripps Research Inst Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2)
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
MX2011010159A (es) 2009-04-02 2011-10-17 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla.
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
AR080793A1 (es) * 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102221615A (zh) * 2011-03-31 2011-10-19 广州华灿医药科技有限公司 一种基于Angiogenin检测的双抗夹心ELISA方法
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2012137993A1 (en) * 2011-04-05 2012-10-11 Neopharm Co., Ltd. Antibodies against angiopoietins 1 and 2, and their use
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
EP2760471B9 (en) 2011-09-30 2017-07-19 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
RU2644341C2 (ru) 2012-02-10 2018-02-08 Дженентек, Инк. Одноцепочечные антитела и другие гетеромультимеры
CN104379604A (zh) * 2012-05-24 2015-02-25 弗·哈夫曼-拉罗切有限公司 多特异性抗体
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
CA2871882A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
HRP20211641T1 (hr) 2012-07-13 2022-02-04 Roche Glycart Ag Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
KR101967345B1 (ko) 2012-10-18 2019-04-09 삼성전자주식회사 안지오포이에틴-2와 인테그린 간의 결합을 저해하는 펩타이드 및 그 용도
WO2014108854A1 (en) * 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
JP6469644B2 (ja) 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド 抗ccr7抗原結合タンパク質に関係する方法および組成物
JP6397886B2 (ja) 2013-03-15 2018-09-26 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 治療用ペプチド
KR102131371B1 (ko) 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 특이적 항체 및 그의 용도
EP3381940B1 (en) 2013-07-29 2022-09-07 Samsung Electronics Co., Ltd. Anti-ang2 antibody
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
MX2016008099A (es) * 2013-12-20 2016-10-13 Hoffmann La Roche Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40.
KR102206029B1 (ko) 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
CA2939006A1 (en) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
US9957333B2 (en) * 2014-04-17 2018-05-01 Case Western Reserve University Anti-CEP antibody or fragment thereof
AR100270A1 (es) 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
US9994632B2 (en) 2014-05-26 2018-06-12 Samsung Electronics Co., Ltd. Humanized or affinity-matured anti Ang-2 antibody and uses thereof
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
CA2964470A1 (en) * 2014-10-17 2016-04-21 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
AU2015345321A1 (en) * 2014-11-10 2017-04-20 F. Hoffmann-La Roche Ag Anti-ANG2 antibodies and methods of use
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
EP3250586B1 (en) * 2015-01-28 2021-10-27 Pieris Pharmaceuticals GmbH Novel proteins specific for angiogenesis
CN108136001B (zh) 2015-04-03 2022-07-29 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
WO2017030909A1 (en) 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf
CN116987187A (zh) 2015-09-23 2023-11-03 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
SG10201911499TA (en) 2015-11-30 2020-01-30 Pieris Australia Pty Ltd Novel anti-angiogenic fusion polypeptides
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
KR102143132B1 (ko) * 2016-12-26 2020-08-10 기초과학연구원 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물
AU2018240375C1 (en) 2017-03-22 2024-02-01 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CN110612124B (zh) 2017-03-22 2024-04-16 豪夫迈·罗氏有限公司 用于治疗眼部病症的优化的抗体组合物
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
KR102497171B1 (ko) * 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣3多肽之持續遞送
CN113728004A (zh) * 2019-02-25 2021-11-30 药物抗体公司 抗Ang2抗体及其用途
TW202115112A (zh) * 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
WO2021183849A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2021194913A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
EP4183802A1 (en) * 2020-06-22 2023-05-24 Innovent Biologics (Suzhou) Co., Ltd. Anti-ang-2 antibody and use thereof
CA3198668A1 (en) 2020-10-15 2022-04-21 Genentech, Inc. Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics
WO2024064640A2 (en) * 2022-09-19 2024-03-28 Sonoma Biotherapeutics, Inc. Citrullinated antigen-specific chimeric antigen receptors for targeting regulatory t cells to treat hidradenitis suppurativa

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
RU2277411C1 (ru) * 2004-12-15 2006-06-10 Ольга Алексеевна Кост Фармацевтическая композиция для лечения глазных болезней, связанных с нарушением микроциркуляции и/или воспалительными процессами
CN105085678B (zh) * 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
CA2799802A1 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
ES2390354T3 (es) * 2005-07-22 2012-11-12 Amgen, Inc Liofilizados de proteínas concentrados, procedimientos y usos
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
CA2633211A1 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007087673A1 (en) * 2006-02-01 2007-08-09 Arana Therapeutics Limited Domain antibody construct
JP5596559B2 (ja) * 2008-01-28 2014-09-24 メディミューン リミテッド 安定化アンジオポエチン2抗体とその用途
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
HRP20211641T1 (hr) * 2012-07-13 2022-02-04 Roche Glycart Ag Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti

Also Published As

Publication number Publication date
NZ600005A (en) 2012-08-31
US20130156789A1 (en) 2013-06-20
TWI482631B (zh) 2015-05-01
RU2011129204A (ru) 2013-01-27
CR20130418A (es) 2013-10-04
BR122013022089B1 (pt) 2021-10-13
AU2009328613A1 (en) 2010-06-24
US20140065707A1 (en) 2014-03-06
US20200262904A1 (en) 2020-08-20
ECSP11011139A (es) 2011-07-29
RU2569107C2 (ru) 2015-11-20
UA103912C2 (uk) 2013-12-10
HK1195775A1 (zh) 2014-11-21
PE20120551A1 (es) 2012-05-21
CN103739709B (zh) 2016-08-24
US9340609B2 (en) 2016-05-17
IL226350A0 (en) 2013-06-27
JP2012511897A (ja) 2012-05-31
JP5814317B2 (ja) 2015-11-17
HRP20150439T1 (hr) 2015-05-22
US20120141500A1 (en) 2012-06-07
BRPI0923434A2 (pt) 2017-09-19
PL2379592T3 (pl) 2015-07-31
CA2916481A1 (en) 2010-06-24
TW201322996A (zh) 2013-06-16
PH12013502192B1 (en) 2015-10-12
US8361747B2 (en) 2013-01-29
DK2379592T3 (en) 2015-03-02
US8399626B2 (en) 2013-03-19
PE20140814A1 (es) 2014-07-10
ZA201307297B (en) 2019-07-31
RU2569461C2 (ru) 2015-11-27
CL2011001285A1 (es) 2011-09-16
UA105151C2 (uk) 2014-04-10
US20210388071A1 (en) 2021-12-16
WO2010069532A1 (en) 2010-06-24
HK1172349A1 (zh) 2013-04-19
CN102746400B (zh) 2015-12-16
US9109027B2 (en) 2015-08-18
US20170029493A1 (en) 2017-02-02
IL213039A (en) 2015-03-31
MY158438A (en) 2016-10-14
AR092487A2 (es) 2015-04-22
US20180282404A1 (en) 2018-10-04
ES2534635T3 (es) 2015-04-27
EP2379592B1 (en) 2015-02-11
MA32876B1 (fr) 2011-12-01
US20140065151A1 (en) 2014-03-06
US20100159587A1 (en) 2010-06-24
US20230227543A1 (en) 2023-07-20
CN102257008A (zh) 2011-11-23
ECSP13011139A (es) 2014-10-31
CA2916481C (en) 2018-05-15
KR20110084536A (ko) 2011-07-25
CR20110321A (es) 2011-07-14
NZ592856A (en) 2012-06-29
KR101381012B1 (ko) 2014-04-11
AR074756A1 (es) 2011-02-09
US8133979B2 (en) 2012-03-13
PT2379592E (pt) 2015-03-24
CN103739709A (zh) 2014-04-23
CA2744624C (en) 2018-01-02
IL213039A0 (en) 2011-07-31
KR101445518B1 (ko) 2014-10-01
US20120142091A1 (en) 2012-06-07
JP5559191B2 (ja) 2014-07-23
SG172216A1 (en) 2011-07-28
US20150284457A1 (en) 2015-10-08
BR122013022089A2 (pt) 2019-05-28
TW201026328A (en) 2010-07-16
ZA201103990B (en) 2016-01-27
SI2379592T1 (sl) 2015-06-30
RU2013140625A (ru) 2015-03-10
PH12013502192A1 (en) 2015-10-12
MX2011005908A (es) 2011-06-20
US9073986B2 (en) 2015-07-07
CN102746400A (zh) 2012-10-24
JP2014000089A (ja) 2014-01-09
EP2379592A1 (en) 2011-10-26
CA2744624A1 (en) 2010-06-24
CY1116264T1 (el) 2017-02-08
AU2009328613B2 (en) 2013-09-05
TWI396549B (zh) 2013-05-21
HUE024545T2 (hu) 2016-01-28
IL226350A (en) 2016-10-31
MY155654A (en) 2015-11-13
WO2010069532A8 (en) 2012-05-10
KR20130103822A (ko) 2013-09-24

Similar Documents

Publication Publication Date Title
CL2012003054A1 (es) Anticuerpos contra la angiopoyetina 2 humana (ang-2); composicion farmaceutica que contiene dicho anticuerpo; uso del anticuerpo para preparar medicamento destinado a la prevencion de metastasis; acido nucleico que codifica dicho anticuerpo; vector de expresión.
NZ601374A (en) Stabilized antibody-containing liquid formulations
CL2013000669A1 (es) Agente de union a cd33 que se une al cd33 humano; molecula de adn que codifica la region variable de cadena pesada de un agente de union a cd33; vector de expresion; celula hospedante; metodo para reducir agente de unión a cd33; composicion farmaceutica; uso de la composicion farmaceutica para disminuir el numero de celulas que expresan el cd33 sobre su superficie.
CL2013000074A1 (es) Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos.
CL2013001124A1 (es) Anticuerpo aislado o una proteína que comprende una porción de enlace de antígeno de un anticuerpo dirigido contra un polipéptido de cd40; composicion farmacéutica que comprende dicho anticuerpo; ácido nucleico que codifica el anticuerpo; vector de clonación; proceso de producción del anticuerpo.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
BR112014026755A2 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
AR095374A1 (es) Moléculas de unión para bcma y cd3
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
CL2013002828A1 (es) Anticuerpo o fragmento de union especifico para la proteina del oncogen de wilms (wt1) unido a hla-a2; acido nucleico; vector de expresion; celula para la expresion del anticuerpo; metodo para la deteccion de wt1; composicion farmaceutica; metodo para matar celula wt1+; kit para la deteccion wt1; uso para fabricar un medicamento
CL2013001831A1 (es) Proteina de enlace multivalente y multiespecifica que une a il-1 alfa y beta; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos.
CR20110166A (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2
GT201300186A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
CL2009000379A1 (es) Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer.
CL2008002873A1 (es) Anticuerpo anti-glipican 3/gpc3; composicion que lo comprende; agente anti-canceroso que lo comprende; acido nucleico que codifica dicho anticuerpo; celula hospedera aislada que comprende dicho acido nucleico; metodo para la preparacion de dicho anticuerpo
BR112012020372A2 (pt) "naticorpo que se liga ao csf- 1r humano, composição farmaceutica acido nucleico vetoresde expressão, célula hospedeira e método para a produção de um anticorpo recobinante
CL2013001279A1 (es) Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
EA201300388A1 (ru) Соединения замещенного бензамида
BR112013005699A2 (pt) moléculas de ligação a 4-1bb
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
CO6351748A2 (es) Anticuerpos contra il-6 y sus usos
EA201171246A1 (ru) Содержащая трегалулозу композиция, ее получение и применение
UY33380A (es) Formulaciones farmacéuticas que contienen derivados de 1-(b(beta)-d-glucopiranosilo) y sus usos
ECSP11011095A (es) Amidas del ácido 4-(1,2,3,4-tetrahidroisoquinolina-2-il)-4-oxobutírico sustituidas como moduladores de KCNQ2/3.
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol